T1	p 93 132	advanced epithelial ovarian carcinoma .
T2	p 214 224	previously
T3	p 234 245	multicentre
T4	p 296 394	patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen .
T5	p 416 464	Patients with bidimensionally measurable disease
T6	p 601 637	Patients were eligible for treatment
T7	p 942 967	constipation and insomnia
T8	p 982 1018	total of 226 patients were evaluable
T9	p 1023 1031	response
T10	p 1368 1394	4 years post-randomisation
T11	p 1941 1960	of ovarian cancer .
T12	i 62 89	topotecan versus paclitaxel
T13	i 265 292	topotecan versus paclitaxel
T14	i 484 493	topotecan
T15	i 507 508	2
T16	i 511 515	/day
T17	i 527 544	) or paclitaxel (
T18	i 556 557	2
T19	i 560 564	/day
T20	i 574 584	infusion )
T21	i 647 664	alternate therapy
T22	i 1162 1171	topotecan
T23	i 1279 1289	paclitaxel
T24	i 1292 1296	14.7
T25	i 1420 1429	topotecan
T26	i 1509 1519	paclitaxel
T27	i 1522 1526	53.0
T28	i 1605 1614	Topotecan
T29	i 1920 1929	topotecan
T30	o 6 15	Long-term
T31	o 177 185	survival
T32	o 685 706	European Organisation
T33	o 737 792	Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire
T34	o 870 969	pain , anorexia , diarrhoea , fatigue , nausea and vomiting , dyspnea , constipation and insomnia )
T35	o 1131 1137	QOL-30
T36	o 1180 1206	median time to progression
T37	o 1397 1412	median survival
T38	o 1651 1672	efficacy and survival
T39	o 1707 1775	non-cumulative haematological toxicity . Non-haematological toxicity
T40	o 1817 1840	long-term survival rate